Table 5. Pathology and Pathways.
| CIS-ness (%) | Acinar-ness (%) | Papillary-ness (%) | Solid-ness (%) | |||||
| Pathway Name | Coefficient | P-value | Coefficient | P-value | Coefficient | P-value | Coefficient | P-value |
| Intercept | 6.32 | <0.0001 | 34.72 | <0.0001 | 30.34 | <0.0001 | 26.92 | <0.0001 |
| Cell Cycle (+) | −5.65 | <0.0001 | 4.38 | 0.031 | −8.89 | <0.0001 | 7.41 | 0.0011 |
| ESC | NA | NA | NA | NA | NA | NA | NA | NA |
| B-cell | NA | NA | −4.04 | 0.034 | NA | NA | 3.53 | 0.080 |
| T-cell | NA | NA | NA | NA | NA | NA | NA | NA |
| Antigen | NA | NA | NA | NA | NA | NA | NA | NA |
| AKT/PI3K | 1.58 | 0.072 | NA | NA | NA | NA | NA | NA |
| IGF-1 | NA | NA | 6.81 | 0.0001 | −3.95 | 0.028 | NA | NA |
| Chemokine | NA | NA | NA | NA | NA | NA | NA | NA |
| NF-κB | NA | NA | NA | NA | NA | NA | NA | NA |
| Notch | NA | NA | NA | NA | 5.28 | 0.0068 | −6.85 | 0.0007 |
| JAK/STAT | NA | NA | NA | NA | NA | NA | 3.081 | 0.14 |
| Complement | NA | NA | 5.61 | 0.0014 | NA | NA | −6.53 | 0.0015 |
| mTOR | NA | NA | −4.99 | 0.015 | NA | NA | 3.65 | 0.087 |
| Cell Cycle (−) | NA | NA | 2.7 | 0.077 | NA | NA | NA | NA |
| Angiogenesis | NA | NA | −3.39 | 0.042 | −5.34 | 0.0052 | 8.21 | <0.0001 |
| IL-stimulatory | −2.32 | 0.012 | NA | NA | NA | NA | NA | NA |
| IL-suppressive | NA | NA | NA | NA | NA | NA | NA | NA |
| Interferon | NA | NA | NA | NA | NA | NA | NA | NA |
| EGFR | NA | NA | −4.29 | 0.0035 | 5.58 | 0.0003 | NA | NA |
| PDGF | NA | NA | 3.68 | 0.025 | NA | NA | NA | NA |
| Hypoxia | NA | NA | NA | NA | NA | NA | NA | NA |
| PTEN | NA | NA | NA | NA | NA | NA | NA | NA |
| Pro-apoptosis | NA | NA | NA | NA | NA | NA | −3.71 | 0.16 |
| Anti-apoptosis | 1.71 | 0.079 | −3.40 | 0.075 | −3.68 | 0.056 | 6.21 | 0.0079 |
| TGF-β | NA | NA | NA | NA | NA | NA | NA | NA |
| Hedgehog | NA | NA | NA | NA | 3.77 | 0.028 | −4.45 | 0.010 |
| Wnt | NA | NA | 2.36 | 0.13 | −3.10 | 0.087 | −4.10 | 0.025 |
Carcinoma in situ (CIS) tumors are best described by relative underexpression of the cell cycle stimulatory (CC+) pathway. This relationship was consistent when taking into account only the presence or absence (+/−) of a CIS component of the tumor as well as the percentage (%) of the tumor that was CIS. Acinar tumors tended to have relative overexpression of the complement and PDGF pathways and relative underexpression of the angiogenesis pathway. Relative underexpression of the CC+ pathway was a strong indicator of papillary tumors as were relative overexpression of the EGFR and hedgehog pathways. Solid tumors were best defined by relative overexpression of the CC+, JAK/STAT and angiogenesis pathways and by relative underexpression of the Notch pathway. NA means the variable was excluded during model selection.